NCT01946425View on ClinicalTrials.gov

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

July 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative

0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)

BIOLOGICAL

Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative

0.5 mL, Intramuscular (2013-2014 formulation)

Trial Locations (2)

40040

Bardstown

84121

Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01946425 - Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine | Biotech Hunter | Biotech Hunter